XERS Q4 2024 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M+35.4% YoY

Gross Profit

$51M84.2% margin

Operating Income

$2M2.8% margin

Net Income

-$5M-8.5% margin

EPS (Diluted)

$-0.03

QoQ Revenue Growth

+10.7%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$2M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$323M

Total Liabilities

$353M

Stockholders' Equity

-$30M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$44M	+35.4%
Gross Profit	$51M	$34M	+48.4%
Operating Income	$2M	-$10M	+117.1%
Net Income	-$5M	-$13M	+61.8%

Revenue Segments

Product

$104M81%

Keveyis

$24M19%